Immutil-S 180 Tablet DR contains Mycophenolate sodium 180 mg, an immunosuppressive agent primarily indicated for the prevention of organ transplant rejection. Mycophenolate sodium selectively inhibits inosine monophosphate dehydrogenase, a key enzyme in the de novo synthesis of guanosine nucleotides, thereby suppressing the proliferation of T and B lymphocytes which are critical in the immune response. This delayed-release formulation enhances gastrointestinal tolerability by minimizing direct gastric irritation. Immutil-S 180 is commonly prescribed as part of combination immunosuppressive regimens following renal, cardiac, or hepatic transplantation to reduce the risk of acute and chronic allograft rejection. The drug should be administered under strict medical supervision with regular monitoring of hematologic parameters, renal and hepatic function, and signs of infection due to its immunosuppressive effects. Adverse reactions may include gastrointestinal disturbances, leukopenia, anemia, and increased susceptibility to infections. Caution is advised in patients with active infections or hematologic abnormalities. Pregnancy is contraindicated due to the risk of fetal harm. Dose adjustments may be necessary in patients with renal impairment. Immutil-S 180 should be stored at controlled room temperature and kept out of reach of children. Proper adherence to prescribed dosing schedules is essential to optimize therapeutic outcomes and minimize adverse effects.